Inflammatory markers in hyperlipidemia: from experimental models to clinical practice.

Current pharmaceutical design

Volumn 17, Issue 37, 2011, Pages 4132-4146

  Siasos, Gerasimos ^a   Tousoulis, Dimitris ^b   Oikonomou, Evangelos ^b   Zaromitidou, Marina ^b   Stefanadis, Christodoulos ^b   Papavassiliou, Athanasios G ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BIOLOGICAL MARKER; LIPID;

ANIMAL; ATHEROSCLEROSIS; BLOOD; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG EFFECT; HUMAN; HYPERLIPIDEMIA; IMMUNOLOGY; INFLAMMATION; LIPID METABOLISM; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; INFLAMMATION; LIPID METABOLISM; LIPIDS;

MLCS; MLOWN;

EID: 84860742956     PISSN: None     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798764780     Document Type: Review

References (0)